SimBioSys
Private Company
Total funding raised: $33M
Overview
SimBioSys is a private, clinical-stage company leveraging artificial intelligence, spatial biophysics, and data science to create comprehensive 3D models of solid tumors. Its core platform, PhenoScope, generates 'digital twins' to simulate drug distribution and tumor response, aiming to answer critical clinical questions across surgery, therapy selection, and dosing. While its first commercial product is an FDA-cleared surgical visualization tool for breast cancer, the company has a broader pipeline of in-development diagnostic and predictive software tools for various solid tumors.
Technology Platform
AI-powered platform combining Convolutional Neural Networks for tumor segmentation, spatial biophysics to model drug transport and tumor microenvironment dynamics, and data science to create predictive 3D 'digital twin' models of solid tumors.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
SimBioSys operates in the competitive AI-powered medical imaging and computational oncology space. It differentiates itself through its deep integration of spatial biophysics to create dynamic 'digital twin' models, going beyond many competitors focused solely on image analysis or radiomic feature extraction. It competes with other AI diagnostics startups and large medtech firms developing tools for tumor segmentation and outcome prediction.